NKGen Biotech, Inc. NKGN
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $8.8M
- P/E
- 0.0×
Follow NKGN
Growth Flags
show if company had growth for consecutive years
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '17 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | — |
P/S ratio |
— | — | 0.00 | — | — |
P/FCF ratio |
— | — | 0.00 | — | — |
P/Operating CF |
— | — | (11.57) | — | — |
P/B ratio |
— | — | 40.46 | — | — |
Price to Tangible BV |
— | — | 40.46 | — | — |
EV/Sales |
— | — | 0.00 | — | — |
EV/EBITDA |
— | — | 0.00 | — | — |
EV/Operating CF |
— | — | (3.32) | — | — |
EV/FCF |
— | — | (3.32) | — | — |
Quick Ratio |
0.00 | 0.01 | 0.01 | 0.91 | — |
Current Ratio |
0.04 | 0.05 | 0.02 | 1.34 | — |
Net Debt/EBITDA |
(1.69) | (0.34) | (0.50) | 0.69 | — |
Debt/Assets |
267.97% | 60.25% | 71.37% | 0.00% | 0.00% |
Debt/Equity |
(0.62) | (0.17) | 7.46 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.47 | 0.26 | 0.84 | 1.54 | — |
Capex/Depreciation |
(0.01) | (0.04) | (0.13) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | — |
| 68.87% | 290.40% | 573.40% | 0.00% | — | |
| (270.76%) | (505.65%) | (28.09%) | (1.14%) | — | |
ROIC |
0.00% | 0.00% | (116.15%) | 0.00% | — |
Return on Tangible Assets |
104.91% | 359.68% | (2,367.61%) | (154.28%) | — |
Average Days of Receivables |
— | — | 137.47 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 21,748.05% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 9,946.75% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 89.61% | 0.00% | — |
Graham Net Nets |
— | — | (0.23) | — | — |
Graham Number |
— | — | 0.00 | — | — |
Earnings Yield |
— | — | (42.28%) | — | — |
Free Cash Flow Yield |
— | — | (35.67%) | — | — |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | — |
Operating CF per Share |
(0.72) | (1.42) | (3.55) | (0.10) | — |
Capex per Share |
0.00 | 0.00 | (0.03) | 0.00 | — |
Free Cash Flow per Share |
(0.72) | (1.43) | (3.57) | (0.10) | — |
Cash per Share |
0.01 | 0.02 | 0.02 | 0.11 | — |
Shareholders Equity per Share |
(2.42) | (3.80) | 0.25 | (0.72) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(2.42) | (3.80) | 0.25 | (0.72) | — |
Free Cash Flow |
(20.89) | (22.00) | (22.72) | (1.52) | — |
Working Capital |
(55.51) | (37.52) | (14.39) | 0.64 | — |
Capital Expenditures |
(0.01) | (0.05) | (0.16) | — | — |
Net Current Asset Value |
(83.68) | (73.24) | (14.42) | (182.55) | — |
EV/EBIT |
— | — | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 2.12 | — | — |
Net Profit Margin |
0.00% | 0.00% | (34,745.45%) | 0.00% | — |
Price to Operating Income |
— | — | 0.00 | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.10 | 0.08 | 0.08 | — | — |
Cash ROIC |
130.56% | 75.09% | (285.55%) | 16.61% | — |
Accounts Receivable Turnover |
— | — | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.01 | — | — |
Inventory Turnover |
— | — | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 53,776.67 | 0.00 | — |
Days of Inventory on Hand |
— | — | 0.00 | — | — |
Average Payables |
14.53 | 8.02 | 1.35 | — | — |
Average Assets |
16.36 | 16.41 | 95.26 | 87.10 | — |
Average Common Equity |
(64.30) | (28.56) | (4.67) | — | — |
Columns are period end dates